All In Biotech

Drug Trial Radar · NCT07728383

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Topical-Lingual Semaglutide (T-L Semaglutide) in Adults With Obesity

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jun 17, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Gila Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

Conditions

  • Obesity & Overweight

Interventions

  • Semaglutide 6 mg liquid emulsion formulationDrug

    Semaglutide 6 mg liquid emulsion formulation daily

  • Wegovy® (semaglutide) TabletDrug

    Wegovy® (semaglutide) Tablet 25 mg daily

  • Placebo liquid emulsion formulationDrug

    Placebo liquid emulsion formulation daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent body weight change from baselineTime frame: 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Institute of Minnesota

    Minneapolis, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.